Antigout. Xanthine oxidase inhibitor, thereby reducing the synthesis of uric acid.
Pharmacokinetics: Allopurinol is rapidly absorbed from the upper gastrointestinal tract. It is converted in the body to the pharmacologically active metabolite alloxanthine (oxypurinol). It is well distributed in the body; the main excretory pathway for allopurinol and its metabolite is via the kidneys.
Treatment of primary or secondary hyperuricemia, uric acid nephropathy. Adjuvant treatment of gout; recurrent uric stone formation. Prophylactic treatment to prevent tissue deposition, renal calculi or uric acid nephropathy in patients with leukemia, lymphomas and malignancies who are receiving cancer chemotherapy with its resultant elevating effect on serum uric acid levels.
The average daily dose is 100-300 mg for those with moderately severe cases, larger amounts should be taken in divided doses or as prescribed by the physician. Allopurinol is best taken after food.
Pregnancy and lactation. Hypersensitivity to allopurinol.
Discontinue Loricid at the first sign of skin rash or any sign of adverse reaction.
Renal failure and concurrent thiazide therapy predispose to hypersensitivity. Risk of precipitating acute gout during initial therapy is reduced by prophylactic doses of colchicine. Fluid intake should be sufficient to maintain urinary output not less than 2 L/day particularly when uricosurics are given concomitantly. Reduce dosage of allopurinol in renal failure. Liver and kidney function should be monitored and complete blood counts performed particularly during the 1st month of therapy.
Effects on the Ability to Drive or Operate Machinery: Impaired ability to operate motor vehicles or other dangerous machinery may occur.
Loricid is contraindicated in pregnancy and lactation.
Severe allergic reactions may include blood dyscrasias. Stevens-Johnson syndrome and more rarely, vasculitis leading to liver damage and acute renal failure.
Allopurinol delays the metabolic breakdown of mercaptopurine and azathioprine; when these drugs are given concomitantly with allopurinol, ¼ of the usual dosage of mercaptopurine or azathioprines should be given. The t½ of anticoagulants, dicumarol, may be prolonged by allopurinol.
Coagulation time should be assessed if allopurinol is added to or removed from the patient's drug regimen.
Store at room temperature.
M04AA01 - allopurinol ; Belongs to the class of preparations inhibiting uric acid production. Used in the treatment of gout.